Natriuretic peptide, C-type

Base Information

• Chemical Name: Natriuretic peptide, C-type
• CAS No.: 127869-51-6
• Molecular Formula: C93H157 N27 O28 S3
• Molecular Weight: 2197.6
• DSSTox Substance ID: DTXSID60155686
• Wikidata: Q78190979
• Mol file: 127869-51-6.mol

Synonyms:C Type Natriuretic Peptide;C Type Natriuretic Peptide 22;C Type Natriuretic Peptide 53;C-Type Natriuretic Peptide;C-Type Natriuretic Peptide-22;C-Type Natriuretic Peptide-53;CNP-22;CNP-53;Natriuretic Peptide, C Type;Natriuretic Peptide, C-Type;Natriuretic Peptide-22, C-Type;Natriuretic Peptide-53, C-Type;Peptide, C-Type Natriuretic;Peptide-22, C-Type Natriuretic;Peptide-53, C-Type Natriuretic

Chemical Property of Natriuretic peptide, C-type

Chemical Property:

• PSA: 962.25000
• Density: 1.46±0.1 g/cm3(Predicted)
• LogP: 0.46880
• Storage Temp.: −20°C
• XLogP3: -8.7
• Hydrogen Bond Donor Count: 32
• Hydrogen Bond Acceptor Count: 35
• Rotatable Bond Count: 44
• Exact Mass: 2196.0853510
• Heavy Atom Count: 151
• Complexity: 4490

Purity/Quality:

98%,99%, ^*data from raw suppliers

Natriuretic Peptide, C-Type ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CN)C(=O)O)CC(C)C)CO)CCSC)CO
• Isomeric SMILES: CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)O)CC(C)C)CO)CCSC)CO
• Recent ClinicalTrials: The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels
• Biological functions: CNPs do not induce natriuresis at physiological concentrations. In mammals, the most recognized function of CNP is the regulation of long bone growth. CNP targets chondrocytes to promote endochondral ossification. CNP also has a vasodepressor effect in mammals, teleosts (the eel and trout) and elasmobranchs, presumably through its action on the vascular smooth muscle. In the medaka that lack npr1, CNP3 appears to be important for normal atrial development, as CNP3 knockdown resulted in the hypertrophy of the atrium. Thus, CNP3 appears to take over the roles of ANP in this teleost. In the shark, CNP3 stimulates the release of vasoactive intestinal peptide (VIP) from the nerve terminals within the rectal gland.
• Description: CNPs are ancient members of the natriuretic peptide family, which is characterized by the absence of C-terminal tail extensions from the intramolecular ring. In mammals, CNP is highly expressed in the brain, vascular endothelial cells, and chondrocytes, and acts locally as a paracrine/autocrine factor. CNP was isolated in 1990 from the killifish brain, and shortly thereafter from the pig brain. Four distinct CNPs (CNP1–4) were then discovered in 2003 from teleost genome databases. Later, comparative genomic analyses inferred that only CNP4 is retained in mammals, CNP1 and CNP3 in birds, CNP3 and CNP4 in amphibians, CNP1–4 in most teleosts, CNP3 in elasmobranchs, and CNP4 or CNP4-like NP in cyclostomes.
• Clinical Use: CNP has not been used as a diagnostic or therapeutic tool. Several studies suggested potential uses of CNP, such as for the treatment for growth disorders and as a biomarker of growth plate activity.

Technology Process of Natriuretic peptide, C-type

There total 1 articles about Natriuretic peptide, C-type which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

Fmoc-(rac)-Arg(Pbf)-OH (187618-60-6) + Fmoc-Cys(Trt)-OH (200947-68-8,167015-11-4) + N-(fluoren-9-ylmethoxycarbonyl)glycine (29022-11-5) + 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid (126727-03-5) + 2-(9-fluorenylmethoxycarbonylamino)-3-phenylpropionic acid (126727-04-6) + Fmoc-Gly-Cys(ΨDmp,Hpro)?OH (1926163-05-4) + Fmoc-Asp(OMpe) (180675-08-5,1926162-97-1) + N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)lysine + N-Fmoc-methionine (144701-23-5) + Fmoc-DL-Ser-(OtBu)-OH (205812-07-3) + Fmoc-Ile (251316-98-0) → human C-type natriuretic peptide 22 (127869-51-6)

Guidance literature:

Fmoc-Gly-Cys(Ψ^Dmp,Hpro)?OH; With N-ethyl-N,N-diisopropylamine; In dichloromethane; for 3h; Trt(2-Cl)-resin

With benzotriazol-1-ol; 1,8-diazabicyclo[5.4.0]undec-7-ene; In N,N-dimethyl-formamide; for 0.5h; Trt(2-Cl)-resin

Fmoc-(rac)-Arg(Pbf)-OH; Fmoc-Cys(Trt)-OH; N-(fluoren-9-ylmethoxycarbonyl)glycine; 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid; 2-(9-fluorenylmethoxycarbonylamino)-3-phenylpropionic acid; Fmoc-Asp(OMpe); N²-(((9H-fluoren-9-yl)methoxy)carbonyl)-N⁶-(tert-butoxycarbonyl)lysine; N-Fmoc-methionine; Fmoc-DL-Ser-(OtBu)-OH; Fmoc-Ile; Further stages;

DOI:10.1021/acs.joc.9b02344

upstream raw materials:

Fmoc-(rac)-Arg(Pbf)-OH

Fmoc-Cys(Trt)-OH

N-(fluoren-9-ylmethoxycarbonyl)glycine

2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid

Refernces